Amgen Inc (AMGN) Options Trading Volume Hits 11,700 Contracts, 42.3% of Average Daily Volume
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Amgen Options Activity: Amgen Inc (AMGN) recorded an options trading volume of 11,700 contracts today, equivalent to approximately 1.2 million shares, representing about 42.3% of its average daily trading volume of 2.8 million shares over the past month, indicating heightened market interest in its stock performance.
- High Call Option Volume: Notably, the $340 strike call option has seen significant activity with 1,526 contracts traded today, representing around 152,600 underlying shares, reflecting investor optimism regarding Amgen's potential price increase.
- Humana Options Overview: Concurrently, Humana Inc (HUM) experienced an options trading volume of 3,840 contracts, equivalent to approximately 384,000 shares, which is about 42.2% of its average daily trading volume of 910,465 shares over the past month, indicating strong market engagement.
- Active Put Option Trading: Among Humana's options, the $260 strike put option has traded 853 contracts today, representing approximately 85,300 shares, suggesting investor concerns regarding potential downside risks in its stock price.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 331.000
Low
272.00
Averages
345.87
High
425.00
Current: 331.000
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
